journal article·2018-11-05Open access

Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid

Isabela Angeli de Lima, Najeh Maissar Khalil, Tania Toyomi Tominaga, Anna Lechanteur, Bruno Sarmento, Rubiana Mara Mainardes

Abstract

This paper describes the development and in vitro evaluation of poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with chitosan (CS) for oral delivery of ferulic acid (FA). Nanoparticles were obtained by an emulsion evaporation technique and characterized. Furthermore, we evaluated the scavenging activity over hypochlorous acid (HOCl), the cytotoxicity over tumour cells and the in vitro intestinal permeability. Nanoparticles were spherical with a mean diameter of 242 nm, positive zeta potential and 50% of encapsulation efficiency. The in vitro release in phosphate buffered saline (PBS) (pH 7.4) demonstrated a prolonged and biphasic profile diffusion-controlled. In simulated gastrointestinal fluids, about 15% of FA was released in gastric fluid and a negligible release was observed in the intestinal fluid. In the HOCl scavenging activity and cytotoxicity over B16-F10 and HeLa cells, FA-loaded nanoparticles presented the same efficacy of the free drug. Besides, in the antioxidant and cytotoxic assay, CS contributed to FA effects. In the intestinal permeability study, FA-loaded nanoparticles exhibited a permeation of 6% through the Caco-2 monolayer and 20% through the Caco-2/HT29-MTX/Raji B co-culture. CS-coated PLGA nanoparticles are promising carriers for oral delivery of FA.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · biodegradable polymer synthesis and properties

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy, Laboratory of Pharmaceutical Nanotechnology, Universidade Estadual do Centro-Oeste/UNICENTRO, Guarapuava, Brazil;

Department of Physics, Universidade Estadual do Centro-Oeste/UNICENTRO, Guarapuava, PR, Brazil;

INEB – Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal;

Laboratory of Pharmaceutical Technology and Biopharmacy (LPTB) CIRM, Department of Pharmacy, University of Liege, Liege, Belgium;

i3S – Instituto de Investigação and Inovação em Saúde, Universidade do Porto, Porto, Portugal;

CESPU – Instituto de Investigação e Formação Avançada em Ciências and Tecnologias da Saúde, Gandra, Portugal

Funding

CAPES · Fundação Araucária · Finep · Financiadora de Estudos and Projetos

References (47)

Show source-provided references
1. 10.1016/j.fct.2013.12.02410.1016/j.fct.2013.12.024 ↗
2. 10.1016/j.btre.2014.09.00210.1016/j.btre.2014.09.002 ↗
3. 10.1016/B978-0-12-800268-1.00002-010.1016/B978-0-12-800268-1.00002-0 ↗
4. 10.1016/j.ijbiomac.2014.01.02110.1016/j.ijbiomac.2014.01.021 ↗
5. 10.1016/j.ijpharm.2016.06.13110.1016/j.ijpharm.2016.06.131 ↗
6. 10.1016/j.ijbiomac.2017.04.10310.1016/j.ijbiomac.2017.04.103 ↗
7. 10.1016/j.msec.2015.01.03010.1016/j.msec.2015.01.030 ↗
8. Bhathena J · J Diabetes Metab · 2012 · 6 · 006
9. 10.1016/j.ejps.2017.11.00410.1016/j.ejps.2017.11.004 ↗
10. 10.1016/j.colsurfb.2017.07.03810.1016/j.colsurfb.2017.07.038 ↗
11. 10.1016/j.polymer.2012.02.01510.1016/j.polymer.2012.02.015 ↗
12. 10.1016/j.colsurfb.2012.10.06310.1016/j.colsurfb.2012.10.063 ↗
13. 10.1016/j.biomaterials.2014.07.02610.1016/j.biomaterials.2014.07.026 ↗
14. 10.1007/s11046-018-0253-x10.1007/s11046-018-0253-x ↗
15. 10.1590/s2175-9790201700021613810.1590/s2175-97902017000216138 ↗
16. 10.1016/0168-3659(87)90035-610.1016/0168-3659(87)90035-6 ↗
17. 10.1016/j.ejpb.2012.10.00310.1016/j.ejpb.2012.10.003 ↗
18. 10.1016/j.ijpharm.2013.10.00310.1016/j.ijpharm.2013.10.003 ↗
19. 10.1016/j.ejpb.2008.06.00810.1016/j.ejpb.2008.06.008 ↗
20. 10.1016/j.ijpharm.2009.04.04910.1016/j.ijpharm.2009.04.049 ↗
21. 10.1007/s11095-010-0103-010.1007/s11095-010-0103-0 ↗
22. 10.1201/9780849374555.ch110.1201/9780849374555.ch1 ↗
23. Sahoo SK · 2006 · 139
24. 10.1208/s12249-013-9943-310.1208/s12249-013-9943-3 ↗
25. 10.1016/j.ejphar.2011.09.02310.1016/j.ejphar.2011.09.023 ↗
26. 10.1016/j.jconrel.2004.11.01810.1016/j.jconrel.2004.11.018 ↗
27. 10.1002/bmc.17410.1002/bmc.174 ↗
28. 10.1073/pnas.050817010310.1073/pnas.0508170103 ↗
29. 10.1002/(SICI)1097-0010(19990301)79:3<476::AID-JSFA270>3.0.CO;2-L10.1002/(SICI)1097-0010(19990301)79:3<476::AID-JSFA270>3.0.CO;2-L ↗
30. 10.1021/jf060899p10.1021/jf060899p ↗
31. 10.1016/j.foodchem.2013.10.01910.1016/j.foodchem.2013.10.019 ↗
32. 10.1016/j.micpath.2016.02.00710.1016/j.micpath.2016.02.007 ↗
33. 10.1016/j.brainres.2008.02.09010.1016/j.brainres.2008.02.090 ↗
34. 10.1016/j.neulet.2011.12.01210.1016/j.neulet.2011.12.012 ↗
35. 10.3390/md1304215810.3390/md13042158 ↗
36. 10.3390/molecules1510731310.3390/molecules15107313 ↗
37. 10.3390/ijms16102401110.3390/ijms161024011 ↗
38. 10.3748/wjg.v11.i13.202210.3748/wjg.v11.i13.2022 ↗
39. 10.1016/j.bmcl.2006.05.07810.1016/j.bmcl.2006.05.078 ↗
40. 10.1016/S0141-8130(02)00064-810.1016/S0141-8130(02)00064-8 ↗
41. 10.1016/j.addr.2017.07.01910.1016/j.addr.2017.07.019 ↗
42. 10.1208/s12249-016-0522-210.1208/s12249-016-0522-2 ↗
43. 10.1016/j.biomaterials.2015.07.04510.1016/j.biomaterials.2015.07.045 ↗
44. 10.1016/j.jconrel.2016.04.01210.1016/j.jconrel.2016.04.012 ↗
45. 10.1016/j.colsurfb.2015.11.03910.1016/j.colsurfb.2015.11.039 ↗
46. 10.1016/j.biomaterials.2014.04.10410.1016/j.biomaterials.2014.04.104 ↗
47. 10.1016/j.colsurfb.2017.01.02910.1016/j.colsurfb.2017.01.029 ↗